Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities
Top industry leaders and venture firms unite behind Ukko s efforts to eliminate the world s most prevalent food allergies and sensitivities, including peanuts and gluten
News provided by
Share this article
Share this article
PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 /PRNewswire/ Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, today announced $40 million in new Series B funding. Ukko harnesses artificial intelligence (AI) and protein engineering to develop healthier food and therapies for food allergies. The new funding will allow Ukko to enter clinical trials with its investigational therapeutic for peanut allergy. It will also accelerate development of Ukko s gluten that is designed for people with celiac and other gluten sensitivities. The round was led by Leaps by Bayer – the impact investm